Introduction {#Sec1}
============

Biomarkers have been evaluated for several applications in patients with sepsis including diagnosis of infection, prognostication, and therapeutic guidance. Sepsis is a common and severe condition \[[@CR1], [@CR2]\], responsible for high mortality and morbidity rates and also for reduced quality of life \[[@CR1]--[@CR4]\]. Sepsis biomarkers may provide information beyond what is available using other metrics and could therefore help inform clinical decision-making and potentially improve patient management. For example, more timely and appropriate antibiotic therapy could be administered and unnecessary antibiotics avoided if biomarkers were available that could accurately diagnose sepsis early. Similarly, biomarkers could help physicians monitor the effectiveness of therapeutic decisions and adjust treatment if necessary \[[@CR5]\]. Many potential sepsis biomarkers have been proposed, procalcitonin (PCT) and C-reactive protein (CRP) being the most frequently studied. The Surviving Sepsis Campaign guidelines for the management of sepsis mention that sepsis biomarkers can complement clinical evaluation \[[@CR6]\], but in the Sepsis-3 definition consensus, the role of biomarkers in sepsis diagnosis remains undefined \[[@CR7]\].

In 2010, we published a literature review of biomarkers that had been studied for their potential diagnostic or prognostic role in sepsis \[[@CR8]\]. We concluded that none of the 178 biomarkers identified had "sufficient specificity or sensitivity to be routinely employed in clinical practice" \[[@CR8]\]. In this narrative review, we evaluate the progress that has been made in identifying new sepsis biomarkers since that report and reappraise the utility of such research in the management of patients with sepsis.

Methods {#Sec2}
=======

We searched the Medline database via the PubMed portal between February 2009 and September 2019 using ("biomarker" AND "sepsis") as keywords to identify all studies that evaluated a biomarker in sepsis. There were no restrictions by age or language, and all studies, clinical and experimental, were included. The reference lists from all relevant retrieved manuscripts were further reviewed in order to identify additional studies. For each identified biomarker, the PubMed database was searched again using the biomarker name and the keyword "biomarker."

Newly found biomarkers were added to our previous database. Details related to the methodology used in each study were collected, namely (1) type of study (mono- vs. multicenter, prospective vs. retrospective, experimental vs. clinical), (2) study population (intensive care unit \[ICU\], emergency room, other population), (3) number of studied subjects, (4) reference non-sepsis population, and (5) purpose of study or use of biomarker being tested (diagnostic, prognostic, other clinical roles). Results of receiver operating characteristic (ROC) curve analysis were noted where this technique was used to assess biomarker specificity and sensitivity. The Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool \[[@CR9]\] was used to assess the methodological quality of the studies that included more than 300 patients and performed ROC analysis. For each biomarker, the main pathophysiological role (Additional file [1](#MOESM1){ref-type="media"}, Figure S1) was recorded. We also reported separately biomarkers that had been compared with PCT and/or CRP.

Results {#Sec3}
=======

A total of 5367 studies met our search criteria for the period 2009 to 2019 compared with the 3370 studies retrieved in our previous study \[[@CR3]\]. A total of 80 new biomarkers (54 assessed in clinical studies, 23 in clinical and experimental studies, and 3 in only experimental studies) were added to the list of 178 biomarkers that had previously been identified. Despite a steady increase in the number of published studies related to sepsis biomarkers over time, the number of publications reporting *new* biomarkers has decreased since our prior review (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Changes over time in the **a** number of references meeting our search criteria and **b** number of new biomarkers referred to in identified references

The full list of biomarkers with selected references and major findings are shown in Additional file [1](#MOESM1){ref-type="media"}, Tables S1--9. Of the 258 biomarkers, 69 (27%) were assessed primarily for their diagnostic value, 100 (39%) for their prognostic value, and 89 (34%) for both diagnostic and prognostic purposes. A validation population was used in just 12 studies. Most of the biomarkers (*n* = 216 \[84%\]) have been assessed in fewer than five studies, and 81 (31%) have been studied only once. CRP and PCT are the biomarkers that have been studied most frequently, followed by interleukin (IL)-6, presepsin, and CD64 in 31, 25, and 21 studies, respectively.

Apart from CRP and PCT, only 26 biomarkers have been evaluated in studies that enrolled more than 300 patients (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). In 15 of these 24 studies (63%), sepsis was defined using either the 1992 ACCP/SCCM \[[@CR34]\] or the 2001 International Sepsis Definitions Conference \[[@CR35]\] definitions. In one study, the Sepsis-3 definition \[[@CR7]\] was used. Other studies used definitions based on clinical signs compatible with sepsis or positive blood cultures. Of the 10 biomarkers evaluated for their diagnostic value in more than 300 patients, 6 (60%) were evaluated using receiver operating characteristic (ROC) curve analysis; the area under the curve (AUC) was \> 0.8 for just three of the biomarkers (for inter-alpha inhibitor proteins \[[@CR11]\], CD64 \[[@CR13]\], and IL-6 \[[@CR18]\]). Of the 18 biomarkers evaluated for their prognostic value in more than 300 patients, mortality was the primary study endpoint for 14 (78%); prediction of circulatory failure or organ dysfunction and failure of antibiotic therapy were the primary endpoints in the other studies. ROC curve analysis was used in the analysis of 9 of the 18 biomarkers (50%): the AUC for predicting mortality was \> 0.8 only for pro-adrenomedullin, with a high specificity (specificity, 92%; sensitivity, 75%). In two studies, combining a sepsis biomarker with a severity score improved the predictive value (urokinase plasminogen activator receptor \[uPAR\] + APACHE II AUC, 0.83 \[[@CR19]\]; adrenomedullin + Mortality in Emergency Department Sepsis (MEDS) score AUC, 0.81 \[[@CR27]\]). All the studies that evaluated more than 300 patients and used ROC analysis had a high risk of bias because a pre-specified abnormal biomarker value was used ([Additional file, Table S10](#MOESM1){ref-type="media"}). Table 1Sepsis biomarkers, except for C-reactive protein (CRP) and procalcitonin (PCT), that have been evaluated for their diagnostic value in clinical studies with more than 300 subjectsBiomarker \[ref\]No. of patientsSepsis definitionStudy populationReference groupSensitivity/specificity (%)AUCInterleukin (IL)-27 \[[@CR10]\]702Positive blood culturesPediatric ICU patients with infectionNon-infected critical care patients84/630.75Inter-alpha inhibitor proteins \[[@CR11]\]573Positive blood culturesNeonates with sepsisNeonates with risk factors for sepsis89/990.9Group II phospholipase A2 \[[@CR12]\]525ACCP 1992ED patients with sepsisED patients with suspected infection (with and without SIRS)NR (logistic regression analysis)NRBactericidal/permeability increasing protein \[[@CR12]\]525ACCP 1992ED with sepsisED patients with suspected infection (with and without SIRS)NR (logistic regression analysis)NRCD64 \[[@CR13]\]468International Sepsis Definitions Conference 2001Non-selected ICU population with sepsisICU patients admitted without sepsis89/870.94Selenoprotein P \[[@CR14]\]378ACCP 1992Non-selected population with sepsis or septic shockHealthy individualsNR (no test)NRLipopolysaccharide-binding protein \[[@CR15]\]327ACCP 1992Surgical patients without sepsis at admissionSurgical patients with SIRS without sepsis60/620.66Syndecan-1 \[[@CR16]\]512International Sepsis Definitions Conference 2001Trauma patients (4 h after admission) without sepsisTrauma patients without sepsisNR (logistic regression analysis)NRPresepsin \[[@CR17]\]440Sepsis-3ICU patients with sepsisICU patients without sepsis89/590.76IL-6 \[[@CR18]\]306SIRS and organ dysfunction, systolic blood pressure \< 90 mmHg, or lactate ≥ 4 mmol/L plus infectionED patients with suspected sepsisED patients with SIRS and organ dysfunction, systolic blood pressure \< 90 mmHg, or lactate ≥ 4 mmol/L without infectionNR0.86*ED* emergency department, *ICU* intensive care unit, *COPD* chronic obstructive pulmonary disease, *SIRS* systemic inflammatory response syndrome, *NR* not reported, *AUC* area under the receiver operating characteristic curveTable 2Sepsis biomarkers, except for C-reactive protein (CRP) and procalcitonin (PCT), that have been evaluated for their prognostic value in clinical studies with more than 300 subjectsBiomarker \[ref\]No. of patientsSepsis definitionStudy populationMain findingSensitivity/specificity (%)AUCUrokinase plasminogen activator receptor (uPAR) \[[@CR19]\]1914International Sepsis Definitions Conference 2001Critically ill patients and patients hospitalized in internal medicine wardLevels ≥ 12 ng/mL predicted fatal outcome within 30 daysNR/\> 70%0.7080.83 (when combined with APACHE II score)Plasminogen activator inhibitor (PAI) 1 \[[@CR20]\]1790ACCP 1992Septic patients with disseminated intravascular coagulation (DIC)Levels \> 90 ng/mL predict fatal outcome within 30 daysNR (Kaplan-Meier survival functions)NRInterleukin (IL)-12 \[[@CR21]\]1444Proven peritonitis or mediastinitis and systemic inflammation signsSurgical patientsPre-surgery IL-12-synthesizing capability was low in patients who had fatal sepsis after operationNR0.72Thrombomodulin \[[@CR22]\]1103ACCP 1992Critically ill patients with sepsisLevels \> 14 ng/mL can predict circulatory failure or death---gray zone between 7 and 14 ng/mLNR (logistic regression analysis)NRSyndecan-1 \[[@CR22]\]1103ACCP 1992Critically ill patients with sepsisLevels \> 240 ng/mL can predict circulatory failure or death---gray zone between 70 and 240 ng/mLNR (logistic regression analysis)NRFibrinogen \[[@CR23]\]1103ACCP 1992Critically ill patients with sepsisLevels \< 200 mg/dL related to increased risk of fatal outcomeNR (logistic regression analysis)NRAntithrombin activity \[[@CR23]\]1103ACCP 1992Critically ill patients with sepsisDecrease in activity \> 50% related to increased risk of fatal outcomeNR (logistic regression analysis)NRBrain natriuretic peptide (BNP) \[[@CR24]\]1000International Sepsis Definition Conference 2001ED patientsLevels \> 113 pg/mL can predict fatal outcome within 28 days86/550.73Angiopoietin-2 \[[@CR25]\]931NRCritically ill patients with ARDSPersistently increased levels related to fatal outcome within 90 daysNR (logistic regression analysis)NRProthrombin time (PT) \[[@CR26]\]840Suspected infection plus ≥ 3 signs of systematic inflammatory responseCritically ill patients with sepsisIncrease in PT time within first 7 days of sepsis was higher in patients who died within 28 daysNR (no test)NRAdrenomedullin \[[@CR27]\]837International Sepsis Definitions Conference 2001ED patients sepsisLevels \< 34.4 ng/L predicted fatal outcome within 30 days86/610.770.81 (when combined with Mortality in Emergency Department Sepsis (MEDS) score)Pro-adrenomedullin \[[@CR28]\]896Clinical suspicion of infectionED patients with sepsisLevels ≥ 1.6 nmol/L predicted fatal outcome within 28 days75/920.89Heparin-binding protein \[[@CR29]\]759Suspected infection and at least one clinical sign of systematic inflammatory responseED patients with sepsisLevels \> 30 ng/mL predicted any organ dysfunction development within 72 h78/76 (cross-tabulation analysis)NRD-dimer \[[@CR30]\]684International Sepsis Definitions Conference 2001Emergency department patients with sepsisHigher in non-survivors than survivors within 28 daysNR0.68Troponin \[[@CR31]\]598ACCP 1992Critically ill patientsLevels \> 0.06 ng/mL independent prognostic marker for 28-day mortalityNR (logistic regression analysis)NRYKL-40 \[[@CR32]\]502ACCP 1992Critically ill patientsLevels ≤ 505 ng/mL predicted survival in 90 days53/760.64CD64 \[[@CR13]\]468International Sepsis Definition Conference 2001Critically ill patientsSustained elevated levels were related to non-appropriate antibiotic therapy93/480.74Cell-free DNA \[[@CR33]\]481International Sepsis Definitions Conference 2001ED patientsLevels \> 1.6 μg/mL predicted short-term fatal outcome70/760.77*ARDS* acute respiratory distress syndrome, *NR* not reported, *IL* interleukin, *SOFA* sequential organ failure assessment, *AUC* area under the receiver operating characteristic curve

Forty biomarkers have been compared with CRP and/or PCT for their diagnostic value (Table [3](#Tab3){ref-type="table"}); 9 were shown to have better diagnostic value and 11 improved the diagnostic value of CRP and/or PCT when used in combination with one of these two biomarkers. In 10 of the 23 studies in which these results were reported (43%), patients with systemic inflammatory response syndrome (SIRS) without infection were selected as the reference group; two studies used patients after major surgery as the reference group. A validation group of healthy volunteers was used in 5 studies (22%). Table 3Sepsis biomarkers that were compared with procalcitonin (PCT) and/or C-reactive protein (CRP) for sepsis diagnosisBiomarkerStudy groupReference groupComment \[refs\]**Diagnostic performance similar to or worse than that of PCT and/or CRP** Cell-free DNA (cfDNA)ICU patients with sepsisICU patients with SIRSNo better than PCT \[[@CR36], [@CR37]\] CopeptinED patients with sepsisED patients with SIRSNo better than PCT \[[@CR38]\] ICAM-1Patients with necrotic pancreatitisPatients with sterile necrosisNo better than PCT \[[@CR39]\] Lipopolysaccharide-binding proteinED patients with sepsisED patients with infectionNo better than PCT \[[@CR40]\]Non-critically ill patients with sepsisNon-critically ill patients with infectionNo better than PCT \[[@CR41]\]Children with neutropenia and clinical sepsis and/or bacteremiaChildren with febrile neutropenia without infectionNo better than PCT \[[@CR42]\]Patients with proven bacterial lower respiratory infectionPatients with proven viral lower respiratory infectionNo better than CRP \[[@CR43]\]Patients treated in internal medicine wardHealthy controlNo better than PCT \[[@CR27]\] Pancreatic stone proteinED patients with sepsisED patients without infectionNo better than PCT \[[@CR44]\] sCD22Surgical patients with infection after major operationSurgical patients with SIRS but without infectionEqual value to PCT \[[@CR45]\] Interleukin (IL)-2ICU patients with sepsisICU patients with SIRS without infectionNo better than CRP \[[@CR46]\] IL-1βNeonates with infection and sepsisNeonates with infection without sepsisNo better than CRP \[[@CR47]\] RANTESNeonates with infectionHealthy neonatesNo better than CRP \[[@CR48]\] NeopterinICU patients with sepsisICU patients without sepsisLess accurate than PCT \[[@CR49], [@CR50]\] Macrophage migration inhibitory factor (MIF)Patients with infection in medical ward or EDNo bacterial infectionNo better than PCT \[[@CR51]\] AdrenomedullinNeutropenic patients with sepsisNeutropenic patients with fever and clinically documented infectionNo better than PCT \[[@CR52]\] Pro-adrenomedullinSepsis with organ dysfunction and or shockPatients admitted to coronary unit without infectionNo better than PCT \[[@CR53]\] High-mobility group-box 1 protein (HMGB1)Infected patients admitted in the wardHealthy individualsNo better than CRP or PCT \[[@CR54]\] IL-8Neutropenic children with blood culture positive, and/or fever periods with a documented clinical sepsis and/or local infectionNeutropenic children with fever and no infectionNo better than CRP \[[@CR55]\] IL-10Patients with bacteremia and SIRS,Patients with SIRS without bacteremiaComparable with PCT \[[@CR56]\] EndocanCritically ill patients with sepsis and organ dysfunctionCritically ill patients with infection and SIRSComparable with PCT \[[@CR57]\] Pro-atrial natriuretic peptide (ANP)Burned patients that received antibiotics and had either microbiological confirmation of infection or antibiotics leaded to an improvement in clinical situationBurned patients without infectionComparable with PCT \[[@CR58]\] Pentraxin 3Mechanically ventilated patients with ventilator associated pneumoniaMechanically ventilated patient \> 48 h without VAPNo better than CRP \[[@CR59]\]Hematological patients with bacteremia and/or septic shockHematological patients with fever without infectionNo better than CRP \[[@CR60]\]**Better diagnostic value than PCT and/or CRP** Thromboelastometry lysis indexPatients with severe sepsisPatients after operation without sepsisBetter than PCT \[[@CR61]\] Decoy receptor 3ICU patients with sepsisICU patients with SIRSPositive when PCT was negative \[[@CR62]\] Group II phospholipase A2 (PLA2-II)ED patients with sepsis and organ dysfunctionED patients with SIRS without infectionBetter than CRP \[[@CR63]\] HepcidinInfants with sepsis and or bacteremiaInfants with SIRS and not sepsisBetter than CRP \[[@CR64]\] sCD163Patients with sepsis admitted to ICUPatients with SIRS without sepsisBetter than PCT \[[@CR65]\] CD64ICU patients with sepsisICU patients without sepsisBetter than PCT and CRP \[[@CR66]\]Patients with ventilator associated pneumonia and sepsisPatients with ventilator associated pneumonia without sepsisBetter than PCT and CRP \[[@CR67]\] Serum amyloid AFull term infants with sepsisFull term infants with risk for sepsis but without sepsisEarlier increase in neonates with early onset sepsis than CRP \[[@CR68]\] Heparin-binding proteinPatients with sepsis for less than 48 hPatients with infection without sepsisBetter than CRP and PCT \[[@CR69]\] Delta-like canonical Notch ligand 1 (DLL1)Patients with abdominal infection or surgical site associated infectionSurgical patients, trauma patients without infection, and healthy volunteersBetter than CRP and PCT \[[@CR70]\]**Conflicting findings** IL-6Critically ill patients with sepsisPatients with SIRS without infectionIL-6 was not found to have lower diagnostic utility compared to PCT (meta-analysis) \[[@CR71]\]Cirrhotic patients with infection at admission to ICUCirrhotic patients without sepsisIL-6 was found to increase earlier than PCT in cirrhotic patients \[[@CR72]\] sCD25ED patients with infectionED patients with suspected infection but finally infection excludedEqual diagnostic value to PCT for diagnosis of infection in ED \[[@CR44]\]Patients admitted in ICU with infection and SIRSPatients with SIRS without sepsisBetter performance than PCT to identify Sepsis I at ICU admission \[[@CR73]\] CalprotectinICU patients with infectionICU patients without sepsisBetter than CRP and PCT \[[@CR74]\]Patients after major operation who developed sepsisPatients after major operation who did not develop sepsisSimilar value to PCT \[[@CR75]\] IL-27Critically ill children with sepsisChildren with SIRS without infectionBetter than PCT \[[@CR76]\]ICU patients with sepsisICU patients without sepsisNo better than PCT \[[@CR77]\] sTREMICU patients with sepsisICU patients with SIRSBetter than PCT \[[@CR78]\]ICU patients with sepsisICU patients with SIRSNo better than PCT and CRP \[[@CR79]\] Presepsin (CD14)ED patients with sepsisED patients with at least two criteria of SIRS without sepsisBetter than PCT in diagnosis of sepsis in ED \[[@CR80]\]Critically ill patients with sepsis and organ dysfunctionCritically ill patients without infectionNo better than PCT regardless of the presence or not of AKI \[[@CR17]\]Neonates with SIRS and positive blood culturesNeonates with SIRS with negative blood culturesBetter than PCT \[[@CR81]\]**Better performance when combined with PCT and/or CRP** IL-6Neonates with infection within the first week of lifeNeonates with suspicion of infection but finally excluded within the first week of sepsisCombination with CRP in neonates with suspected sepsis \[[@CR82]\] CD64Neonates with sepsisHealthy controlsCombination with PCT and CRP for diagnosis of neonatal sepsis \[[@CR83]\] LeptinPatients with community acquired pneumonia with sepsis or complicated intraabdominal infectionSIRS without infection, healthy controlsCombination with CRP \[[@CR84]\] Pro-adrenomedullinSeptic patientsPatients with SIRS without sepsisCombination to PCT \[[@CR53], [@CR85]\] suPARSeptic patients admitted to ICUCritically ill patients with SIRS without infection and healthy controlsCombination with PCT for diagnosis of sepsis on day 1 of sepsis \[[@CR86]\] CD11bPatients with Gram (+) infectionPatients with Gram (−) infectionCombination with CRP for differentiation from Gram (−) infection \[[@CR87]\] FibrinogenNeutropenic patients with sepsisNeutropenic patients with fever without infectionCombination with CRP for diagnosis of sepsis \[[@CR88]\] BNP and antithrombinNeutropenic patients with fever and bacteremiaNeutropenic patients with fever without infectionCombination with PCT for diagnosis of Gram (−) bacteremia \[[@CR88]\] IL-27Pediatric patients with sepsisPediatric patients with SIRS without infectionImprovement of diagnostic accuracy of PCT for diagnosis of sepsis \[[@CR77], [@CR89]\] α-2 macroglobulinSurgical patients with sepsisSurgical patients with SIRS without sepsisCombination with PCT to exclude sepsis in surgical patients \[[@CR90]\] Decoy receptor 3 and uPARPatients with sepsisPatients with SIRS without infection, healthy volunteersCombination with PCT for diagnosis of sepsis \[[@CR91]\]*sTREM* soluble triggering receptor expressed on myeloid cells, *RANTES* regulated on activation, normal T-cell expressed, and secreted

Forty-four biomarkers were tested in 55 clinical studies for their use in answering specific, clinically relevant questions rather than simply for diagnosis and/or prognosis of sepsis in general (Table [4](#Tab4){ref-type="table"}): 20 were assessed for use to diagnose infection in specific groups of critically ill patients where diagnosis may be difficult based on clinical evaluation and laboratory values, 8 were assessed for diagnosis of ARDS or associated endothelial damage in patients with sepsis, 6 were tested for their ability to identify specific infections or type of microorganism, 6 were studied for use in the diagnosis of disseminated intravascular coagulation, 4 were assessed for use in deciding which patients with hematological malignancy or neutropenia had a low risk of infection, 3 were assessed for their ability to diagnose infection before any clinical symptoms, 2 were evaluated for use in assessing the risk of delirium or encephalopathy in patients with sepsis, and 1 was assessed to differentiate between sepsis and graft rejection. Table 4Some examples of biomarkers that have been assessed for use in specific clinical situationsSituationBiomarker*To diagnose infection in patients with a particular pathology/condition* After cardiac surgeryEndocan \[[@CR92]\], CD64 \[[@CR93]\], pancreatic stone protein \[[@CR94]\] After major surgeryPeptidoglycan \[[@CR95]\], elastase \[[@CR96]\], leptin \[[@CR84]\], calprotectin \[[@CR75]\], a proliferation-inducing ligand \[[@CR97]\], α-2 macroglobulin \[[@CR89]\], lipopolysaccharide-binding protein \[[@CR15]\] COPDPentraxin 3 \[[@CR98]\] CirrhosisInterleukin (IL)-6 \[[@CR72]\] TraumaIL-10 \[[@CR99]\], NT-proCNP \[[@CR100]\], P-selectin \[[@CR101]\] Catheter-related infectionsCitrulline \[[@CR102]\] Infants with necrotic enterocolitisIP-10 \[[@CR103]\] Neutropenic patientsLipopolysaccharide-binding protein \[[@CR104]\], pro-adrenomedullin \[[@CR105]\] BurnsIL-8 \[[@CR106]\], MIF \[[@CR107]\] Autoimmune diseasesCD64 \[[@CR108]\]*To diagnose specific types of infection* Gram (−) vs. Gram (+)Fibrin degradation products \[[@CR109]\], lipopolysaccharide-binding protein \[[@CR104]\], CD11b \[[@CR87]\] Virus vs. bacterial infection or co-infectionTransforming growth factor (TGF-β) \[[@CR110]\], tumor necrosis factor (TNF)-α \[[@CR111]\] VAPsuPAR \[[@CR112]\]*Diagnosis of specific conditions* Sepsis vs. graft rejectionLysozyme \[[@CR113]\] Diagnosis of ARDSClub cell secretory protein (CC)-16 \[[@CR114]\], surfactant protein \[[@CR114]\] Vascular leakage risk in ARDSvon Willebrand factor \[[@CR115]\], angiopoietins (1 and 2) \[[@CR25]\], IL-8 \[[@CR116]\], syndecan-1 \[[@CR117]\], HMGB-1 \[[@CR118]\] Recovery from ARDS---endothelial repairsRAGE \[[@CR119]\] Identification of low risk of infection in hematological/oncological patientsIL-6 \[[@CR120], [@CR121]\], IL-8 \[[@CR120]--[@CR122]\], MCP-1 \[[@CR55]\], IL-5 \[[@CR123]\] Identification of infection before clinical symptomsIL-6 \[[@CR124]\], IL-ra \[[@CR125]\], soluble protein C receptors \[[@CR126]\] Risk of encephalopathy/deliriumVCAM \[[@CR127]\], neuron-specific enolase \[[@CR128]\] Disseminated intravascular coagulationP-selectin \[[@CR129]\], protein C \[[@CR130]\], microparticles \[[@CR131]\], matrix-metalloproteinases \[[@CR132]\], thrombin-antithrombin complex \[[@CR133]\], a2PI \[[@CR134]\]*COPD* chronic obstructive pulmonary disease, *ARDS* acute respiratory distress syndrome, *TNF* tumor necrosis factor, *VAP* ventilator-associated pneumonia, *NT-ProCNP* N-terminal pro-C-type natriuretic peptide, *MIF* macrophage migration inhibitory factor, *VCAM* vascular cell adhesion molecule, *IP* interferon-gamma-inducible protein, *sUPAR* soluble urokinase plasminogen receptor, *IL-1ra* IL-1 receptor antagonist, *MCP* monocyte chemoattractant protein, *sRAGE* soluble receptor for advanced glycation end products, *HMGB* high-mobility group-box 1 protein

Discussion {#Sec4}
==========

Our literature search illustrates that although new biomarkers have been proposed, little real progress has been made in identifying biomarkers with clinical significance. Using a similar method of searching for sepsis biomarkers to that of our previous study, we noted that the number of publications related to sepsis biomarkers has increased considerably over the years. The proportion of new biomarkers being identified has decreased, but this may reflect publication bias with journals becoming more selective in deciding what merits publication as the volume of these studies increases. Because of the complexity of the sepsis response with multiple mediators, and the improved sensitivity of many tests enabling identification of smaller concentrations of substances than in the past, it is likely that our list of biomarkers will expand further in the future. However, the potential utility of creating an ever-expanding list of potential biomarkers without a more rigorous framework to evaluate them is questionable. An improved methodological approach is needed in order to assess the utility of sepsis biomarkers in daily clinical practice.

Accurate evaluation of the possible clinical utility of a biomarker requires assessment in a large number of patients \[[@CR5]\], but we identified only a few biomarkers that have been assessed in studies of more than 300 patients. Moreover, many of the biomarkers have been assessed in only a limited number of clinical studies and one third in just a single study. Patients with sepsis represent a very heterogeneous population, and potential biomarkers need to be assessed in studies with a significant number of patients to ensure random distribution of risk factors that may affect the results of the study (e.g., age, organ dysfunction, type of infection, comorbidities). However, the number of patients enrolled in a study is not the only factor to consider when evaluating the potential role of a sepsis biomarker, and of note, none of the large multicenter studies were able to draw conclusions about the biomarker under study that could change clinical practice.

There was considerable diversity in the methods used to assess sepsis-related biomarkers. Most biomarkers were proposed as being useful for diagnosing sepsis simply because they were increased or decreased to a larger extent in septic than in non-septic patients or healthy individuals. Many studies have assessed the sensitivity and specificity of the biomarker for sepsis diagnosis, but identification of sepsis was often based on the commonly used constellation of non-specific clinical and laboratory findings; in the absence of a "gold standard" diagnostic tool, this method cannot conclusively demonstrate the value of the biomarker with respect to diagnosing sepsis. Other parameters, including positive and negative predictive value or likelihood ratios, can provide greater insight into how well a biomarker performs but these were rarely provided \[[@CR135]\]. Similarly, many biomarkers have been used to evaluate sepsis severity using all-cause mortality as the primary endpoint. Importantly, the majority of the studies that evaluated sepsis biomarkers using this method showed only a limited value; it seems highly unlikely that mortality in septic patients is related to only one pathophysiologic process that could be reflected by abnormal levels of a biomarker. Furthermore, the need for another prognostic test can be questioned because clinical data and other laboratory test results, including blood lactate levels, can already reflect severity and the risk of death in septic patients \[[@CR136]\]. Prognostic biomarkers may be useful to triage patients in special environments, such as in the emergency room, when the information provided can help clinicians to decide whether hospitalization is necessary and, if so, on the ICU or on the regular floor. However, in a multicenter trial (TRIAGE III) in which emergency room physicians were asked to incorporate the prognostic information portrayed by abnormal uPAR levels into their triage decisions, there was no effect on mortality rates compared to standard practice without uPAR levels \[[@CR137]\].

To be of value in clinical practice, a biomarker must be shown to provide an answer to a specific, clinically relevant question, rather than just having diagnostic or prognostic value in general. We identified just 55 studies in which a sepsis biomarker was shown to have a potentially useful role by answering a specific clinical question. For example, biomarkers that could identify specific types of infection may help in guiding a more targeted antibiotic therapy, and a biomarker able to identify septic patients at risk of ARDS may influence fluid management in such patients, reducing risks of fluid overload. Further study needs to better evaluate the potential utility and beneficial effects on outcomes of using biomarkers to answer specific clinical questions.

We attempted to categorize the various biomarkers according to their pathophysiological role, although for many it was not possible to identify a clear role, and some have multiple roles. Only a few biomarkers were found to have a role specifically related to sepsis pathophysiology rather than to a more general inflammatory reaction, including presepsin (the N-terminal fragment of the macrophage lipopolysaccharide \[LPS\] receptor), LPS-binding protein (LBP), bactericidal/permeability increasing protein, peptidoglycan, thrombomodulin, and anti-endotoxin core antibodies. Such biomarkers may help transform our understanding of sepsis from a "physiological syndrome to a group of distinct biochemical disorders" \[[@CR138]\] and advance our search for adjunctive sepsis therapies.

CRP and PCT are by far the most widely used and studied biomarkers. Both increase transiently during sepsis, but long enough to allow for their detection, reflecting a real-time response. Although PCT is considered superior to CRP in many studies \[[@CR139], [@CR140]\], it is not a definitive test for diagnosing sepsis because PCT levels can also be increased in other conditions \[[@CR141]\]. PCT, similar to CRP, may be more useful to rule out sepsis than to diagnose it \[[@CR142]--[@CR144]\], and the combination of these two biomarkers may improve their ability to exclude sepsis \[[@CR145]\]. Studying the time course of these biomarkers may also be helpful to evaluate an individual patient's response to therapy. Changes in serum CRP levels during the first 48 h after antibiotic initiation can help evaluate the response to initial antimicrobial therapy \[[@CR146]\]. Likewise, a PCT-based algorithm may help reduce antibiotic exposure in septic patients without compromising clinical outcomes \[[@CR147], [@CR148]\]. However, not all studies have shown the same positive effect \[[@CR149]\], suggesting that the effectiveness of PCT-based algorithms may depend on the physician's experience and the clinical setting. Some biomarkers have been compared to PCT and CRP, most for their diagnostic value. A few were shown to be superior to PCT and/or CRP for this purpose, for example, presepsin and CD64 \[[@CR66], [@CR67], [@CR150]\].

Measuring several biomarkers concurrently may be useful to overcome the limitations of any single biomarker. Combining biomarkers that are involved in different sepsis-related pathways may be particularly attractive. A seven-biomarker panel including cellular markers and interleukins correctly identified 89% of patients with ventilator-associated pneumonia (VAP) and 100% of patients without VAP \[[@CR151]\]. Similarly, a combination of several sepsis-related biomarkers (PCT, presepsin, galectin-3, and soluble suppression of tumorigenicity 2) was found to have better prognostic value than PCT alone \[[@CR152]\]. However, it is not clear from the existing literature whether the biomarkers included in such panels should be selected based on pathophysiological or other criteria. The combination of a biomarker panel with clinical information may be particularly useful in the diagnosis of sepsis or in the risk stratification of patients with sepsis \[[@CR153]\].

The study has some limitations that should be acknowledged. First, although we performed an extensive search, we cannot be sure that some studies were not missed. Nevertheless, the large number of sepsis biomarkers that we retrieved suggests that we managed to identify the majority of the biomarkers that have been studied. Second, we included studies over a long period of time, during which the definition of sepsis has changed so that it is difficult to make comparisons. Third, it is difficult to compare different biomarkers because the methods used to evaluate the biomarkers and to define sepsis and the populations studied varied across the studies.

Conclusions {#Sec5}
===========

Since our original search, many additional sepsis-related biomarkers have been identified. However, the precise roles of most biomarkers in the management of septic patients have not been well defined, and of the many biomarkers that have been studied, only a few have been evaluated in large or repeated studies. As such, it is not possible to draw any reliable conclusions about which compounds could be considered as the most "promising" candidates. Even the biomarkers that had an AUC \> 0.8 for diagnosis or prognosis, making them potentially more interesting for further study, were evaluated in studies with a high risk of bias. Moreover, while there are multiple putative biomarkers, rarely have they been compared against each other to determine how they differ in what they are measuring, and which does it better. Almost all studies report a single marker in isolation, but given the complexity of sepsis, surely these markers are not biologically independent, so how can we know which is best to use?

It is therefore important to develop a more rigorous, standardized methodology to assess sepsis biomarkers and identify those that can provide valuable, clinically relevant information. Such an approach could include the following factors: What is the question being asked? Greater likelihood of infection leading to administration of empiric antibiotics or performance of a diagnostic test (e.g., carcinoembryonic antigen \[CEA\] levels are used to detect early recurrence in patients with colon cancer, and so guide further investigations)Resolution of infection and therefore safety in stopping antibioticsIncreased likelihood of benefiting from specific interventions, such as steroids or a biologic agentIncreased risk of adverse outcome not apparent by other evidenceEnsuring random distribution of risk factors in a randomized controlled trialHow is the study designed? What is the control groupWhich patients and how many are being studiedHow are outcomes adjudicatedIs there a validation cohortUniform techniques to evaluate results---sensitivity, specificity, positive and negative predictive values, likelihood ratios, and ROC analysisIs the marker biologically plausible, and what do alterations tell us about the pathobiology of disease in this patient?

Consideration of these factors and their application to sepsis biomarker research may help identify new biomarkers with real clinical utility. Continuing to produce reports of novel biomarkers without developing a more rigorous framework to evaluate them and establishing a recognized purpose is futile: it is time for a reappraisal of the possible roles of biomarkers in sepsis.
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**Additional file 1: Figure S1.** Biomarkers of sepsis: Time for a reappraisal Pierrakos et al. **Table S1.** Cytokine/chemokine biomarkers identified in the literature search. **Table S2.** Receptor biomarkers identified in the literature search. **Table S3.** Cell marker biomarkers identified in the literature search. **Table S4.** Coagulation-related biomarkers identified in the literature search. **Table S5.** Microcirculation related biomarkers identified in the literature search. **Table S6.** Vasodilation-related biomarkers identified in the literature search. **Table S7.** Biomarkers of organ dysfunction in sepsis identified in the literature search. **Table S8.** Acute phase proteins used as biomarkers in sepsis identified in the literature search. **Table S9.** Diverse sepsis biomarkers identified in the literature search. **Table S10**. QUADAS-2 score \[1145\] for quality assessment for the studies that included \>300 patients where ROC curve analysis was used.

AUC

:   Area under the curve

CRP

:   C-reactive protein

ICU

:   Intensive care unit

IL

:   Interleukin

LBP

:   Lipopolysaccharide-binding protein

LPS

:   Lipopolysaccharide

MEDS

:   Mortality in Emergency Department Sepsis score

PCT

:   Procalcitonin

ROC

:   Receiver operating characteristic

uPAR

:   Urokinase plasminogen activator receptor
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